Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Allergan Inc patents


Recent patent applications related to Allergan Inc. Allergan Inc is listed as an Agent/Assignee. Note: Allergan Inc may have other listings under different names/spellings. We're not affiliated with Allergan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Allergan Inc-related inventors


Sustained release poloxamer containing pharmaceutical compositions

A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose.. ... Allergan Inc

Prostamide-containing intraocular implants and methods of use thereof

Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. ... Allergan Inc

Needle array device

A needle injection array can comprise a plurality of needles that are fluidly interconnected via a fluid manifold. The fluid manifold can be configured to direct fluid from a syringe to arrive at tips of the needles approximately simultaneously. ... Allergan Inc

Artificial tears and therapeutic uses

The present invention provides ophthalmic compositions, e.g. Artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. ... Allergan Inc

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.. ... Allergan Inc

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

Microneedle array with active ingredient

Microneedle arrays for introducing an active ingredient through a skin surface of a subject can include a base layer, a plurality of microneedles projecting from the base layer, and an active ingredient. Each of the microneedles comprises an elongate body having a proximal portion and a distal portion, in which the proximal portion is attached to the base layer. ... Allergan Inc

Implants for sculpting, augmenting or correcting facial features such as the chin

An injectable device, comprising a hyaluronic acid-based composition, useful for long lasting facial sculpting and correction of facial features, for example, for augmenting and shaping the profile, including for example, the chin, jawline or the nose, in a human being is provided. Methods of treatment are also provided.. ... Allergan Inc

Dissolvable microneedles for skin treatment

A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.. ... Allergan Inc

Substance delivery device

A substance delivery device that includes a hypodermic needle with a tube for receiving and containing a volume of a substance. The substance delivery device includes a rod, a portion of which is of a size and shape to fit within the tube of the hypodermic needle. ... Allergan Inc

Compositions & methods for lowering intraocular pressure

Disclosed herein are compositions for lowering intraocular pressure (iop) of an eye comprising a combination iop-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing iop in the eye of a subject.. ... Allergan Inc

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. . ... Allergan Inc

Non-irritating testosterone emulsions

Disclosed herein are emulsions comprising testosterone or related androgens, castor oil, cyclodextrin, pemulen tr-2, polyoxyl 40, and other ingredients. The compositions are useful for treating keratoconjunctivitis sicca and meibomian gland disease.. ... Allergan Inc

Dermal filler compositions including antioxidants

Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin c derivatives. The compositions provide for extended release of active vitamin c into tissue, promoting collagenesis and other benefits to skin.. ... Allergan Inc

07/26/18 / #20180207230

Autoclavable suspensions of cyclosporin a form 2

Disclosed herein are autoclavable formulations of cyclosporin a form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.. . ... Allergan Inc

07/26/18 / #20180207174

Hypotensive lipid-containing biodegradable intraocular implants and related methods

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

07/26/18 / #20180206967

Thread insertion devices

Devices and methods for inserting an implant into skin or other tissue of a patient can include an insertion device having moveable portions that can retain, move, or otherwise control engagement and injection of a hyaluronic thread. The device can include a tubular member and a handle. ... Allergan Inc

07/26/18 / #20180206966

Thread insertion devices

Devices and methods for inserting an implant into skin or other tissue of a patient can include an insertion device having moveable portions that can retain, move, or otherwise control engagement and injection of a hyaluronic thread. The device can include a tubular member and a handle. ... Allergan Inc

07/26/18 / #20180206965

Thread insertion devices

Devices and methods for inserting an implant into skin or other tissue of a patient can include a hyaluronic thread that is coupled at along distal portion with an insertion device. The insertion device can include a cover member and a piston that can collectively facilitate engagement with or disengagement of the distal portion of the thread with the device. ... Allergan Inc

07/26/18 / #20180206964

Thread insertion devices

Devices and methods for inserting an implant into skin or other tissue of a patient can include a hyaluronic thread coupled with an insertion device that can provide a supportive enclosure for the thread as it is injected into a patient's skin or other tissue. The device can include a cover member, a base, and a thread. ... Allergan Inc

07/26/18 / #20180206963

Thread insertion devices

Devices and methods for inserting an implant into skin or other tissue of a patient can include an insertion device that can enclose and support a hyaluronic thread as it is injected into a patient's skin or other tissue. The device can include a cover member, a non-tubular support member, and the thread. ... Allergan Inc

07/19/18 / #20180200045

Soft filled prosthesis shell with discrete fixation surfaces

A soft prosthetic implant shell, such as a silicone breast implant shell, that has discrete fixation surfaces thereon for tissue adhesion. The fixation surfaces may be provided on the posterior face of the shell, as well as either on the periphery or at discrete areas on the anterior face. ... Allergan Inc

07/12/18 / #20180193523

Dermal filler compositions for fine line treatment

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.. . ... Allergan Inc

07/05/18 / #20180185460

Method for treating premature ejaculation with a botulinum neurotoxin

Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.. . ... Allergan Inc

07/05/18 / #20180185385

Preservative free bimatoprost and timolol solutions

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intraocular pressure and treatment of glaucoma.. . ... Allergan Inc

06/28/18 / #20180177718

Implant for treatment of an ocular condition

. . The present disclosure relates to the field of pharmaceutical compositions, ocular implants, and systems and methods for treating an ocular condition. In certain aspects, the disclosure provides ocular implant systems for treating post-operative inflammation. ... Allergan Inc

06/21/18 / #20180170858

Novel ep4 agonists as therapeutic compounds

Described herein are compounds that are ep4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of ep4 receptors.. . ... Allergan Inc

06/21/18 / #20180169086

Compositions containing aromatic aldehydes and their use in treatments

Disclosed are pharmaceutical and cosmetic compositions containing aromatic aldehyde compounds. Some of the disclosed compositions are useful as topical therapeutics for treating inflammatory dermatologic conditions. ... Allergan Inc

06/14/18 / #20180161342

Prostamide-containing intraocular implant

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.. . ... Allergan Inc

06/07/18 / #20180153903

Oil-in-water method for making polymeric implants containing a hypotensive lipid

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

05/31/18 / #20180147307

Methods for sterilizing compositions and resulting compositions

Method for sterilizing a hydrogel composition include subjecting the composition to pulsed light comprising broadband spectrum radiation, the pulsed light being at a dose effective to sterilize the composition without causing significant change in rheology of the composition.. . ... Allergan Inc

05/31/18 / #20180147217

Pharmaceutical compositions and methods of use of 4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (gr) and/or the mineralocorticoid receptors (mr).. ... Allergan Inc

05/17/18 / #20180133401

Adipose tissue combinations, devices, and uses therof

Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction.. ... Allergan Inc

05/10/18 / #20180125951

Methods for alleviating histamine-independent pruritus using neurotoxins

Methods for treating, reducing the occurrence or preventing a histamine-independent pruritic itch using a clostridial toxin derivative are provided herein. In some aspects, the clostridial toxin derivative reduces the itch intensity or duration without affecting thermal or pain sensitivity.. ... Allergan Inc

05/10/18 / #20180125861

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an glucocorticoid derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.. ... Allergan Inc

05/03/18 / #20180119126

Degradable clostridial toxins

The specification discloses clostridial toxins or clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.. . ... Allergan Inc

04/19/18 / #20180105515

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (pk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.. . ... Allergan Inc

04/05/18 / #20180094031

Cyclosporin derivatives wherein the mebmt sidechain has been cyclized

The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin d and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (i/r) injury, including myocardial fr injury, cerebral i/r injury, and ocular or retinal i/r injury.. . ... Allergan Inc

04/05/18 / #20180092726

Dual plane breast implant

A soft breast prosthesis is provided, the prosthesis having a surface configuration advantageous for dual plane placement of the prosthesis in a breast.. . ... Allergan Inc

03/29/18 / #20180086774

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.. ... Allergan Inc

03/22/18 / #20180078674

Heat stable hyaluronic acid compositions for dermatological use

The disclosure provides hyaluronic acid (ha) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. ... Allergan Inc

03/22/18 / #20180078622

Suture line administration technique using botulinum toxins

The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.. ... Allergan Inc

03/22/18 / #20180078606

Methods of providing therapeutic effects using cyclosporin components

Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.. ... Allergan Inc

03/22/18 / #20180078500

Fixed dose combination of brimonidine and timolol

Embodiments disclosed herein are directed to fixed compositions comprising brimonidine and timolol for lowering intraocular pressure and treating glaucoma.. . ... Allergan Inc

03/15/18 / #20180071361

Non-protein clostridial toxin compositions

Pharmaceutical compositions that stabilize a clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. ... Allergan Inc

03/15/18 / #20180071308

Methods for fat reduction

Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.. . ... Allergan Inc

03/15/18 / #20180071260

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.. ... Allergan Inc

03/15/18 / #20180071259

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory t-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.. . ... Allergan Inc

03/08/18 / #20180064721

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

03/08/18 / #20180064720

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

03/01/18 / #20180057576

Complement factor bb antibodies

The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement factor bb. ... Allergan Inc

03/01/18 / #20180056261

Method of manufacturing coated beads

The present specification discloses methods of making porogen compositions, methods of making polymer-coated beads, and methods of making implantable devices that use polymer-coated beads.. . ... Allergan Inc

03/01/18 / #20180055971

Co-crosslinked hyaluronic acid-silk fibroin hydrogels for improving tissue graft viability and for soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.. ... Allergan Inc

02/15/18 / #20180043032

Stabilization of therapeutic agents to facilitate administration

The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated c. ... Allergan Inc

02/15/18 / #20180042932

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

02/08/18 / #20180036252

Pharmaceutical soft gelatin capsule dosage form with modified guar gum

. . A pharmaceutical soft gelatin capsule dosage form that includes (a) a shell that includes gelatin; and (b) a fill that includes at least one active ingredient, one or more polyethylene glycol, and a modified guar gum. The pharmaceutical soft gelatin capsule dosage form maintains its shell integrity (hardness) and fill viscosity after storage.. ... Allergan Inc

02/08/18 / #20180036233

Self-emulsifying drug delivery (sedds) for ophthalmic drug delivery

Provided herein are topical ophthalmic preparations which comprise a non-aqueous, self-emulsifying system which can spontaneously give rise to either nanosized emulsions upon contact with an aqueous phase. Also provided herein are methods for the preparation of the same and their use in formulating and delivering poorly water soluble drugs.. ... Allergan Inc

02/01/18 / #20180029994

Process for the preparation of intermediates useful in the synthesis of eluxadoline

The invention relates to an improved process for preparing [(s)-1-(4-phenyl-1-h-imidazol-2-yl)-ethyl]-amine. The process involves formation of the novel intermediate crystalline compound [(s)-1-(4-phenyl-1-h-imidazol-2-yl)-ethyl]-carbamic acid tert-butyl ester oxalate.. ... Allergan Inc

02/01/18 / #20180028719

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.. ... Allergan Inc

02/01/18 / #20180028624

Injection paradigm for administration of botulinum toxins

Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.. ... Allergan Inc

01/25/18 / #20180021352

Implants and methods for treating inflammation-mediated conditions of the eye

Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodihle polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 μg/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 μg/ml dexamethasone for at least about three weeks.. . ... Allergan Inc

01/25/18 / #20180021348

Hypotensive lipid-containing biodegradable intraocular implants and related implants

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

01/25/18 / #20180021282

Ophthalmic compositions and methods for treating eyes

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.. . ... Allergan Inc

01/25/18 / #20180021254

Compositions containing alpha-2-adrenergic agonist components

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. ... Allergan Inc

01/04/18 / #20180000992

Hyaluronic acid-based gels including lidocaine

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. ... Allergan Inc

01/04/18 / #20180000909

Treatment of psychological trauma

The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a targeted exocytosis modulator, and compositions thereof.. . ... Allergan Inc

12/28/17 / #20170368236

Joint fat pad formulations, and methods of use thereof

The present invention relates to formulations for administration to a joint fat pad of a subject, and to methods of treating joint pain, inflammation or disease. The disclosed formulations are intended for local administration to the joint fat pad to provide sustained release of a therapeutic agent to the joint cavity and surrounding tissues. ... Allergan Inc

12/28/17 / #20170367999

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

12/21/17 / #20170360729

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

12/07/17 / #20170348463

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.. ... Allergan Inc

11/30/17 / #20170342395

Animal product free system and process for purifying a botulinum toxin

Chromatographic processes and systems for purifying a botulinum toxin from an apf fermentation medium.. . ... Allergan Inc

11/30/17 / #20170341949

Production of rounded salt particles

The present disclosure generally relates to methods of preparing spherical salt particles for industrial, medical, and other uses. The methods can include combining the angular salt particles with a quantity of finishing media, for example, into a receptacle. ... Allergan Inc

11/16/17 / #20170327811

Process and system for obtaining botulinum neurotoxin

Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.. . ... Allergan Inc

11/16/17 / #20170327810

Fusion proteins and methods for treating, preventing or ameliorating pain

A single chain polypeptide fusion protein, comprising: a non-cytotoxic protease capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a galanin targeting moiety; a protease cleavage site at which site the fusion protein is cleavable by a protease; a translocation domain capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; a first spacer located between the non-cytotoxic protease and the protease cleavage site; and a second spacer located between the galanin targeting moiety and the translocation domain.. . ... Allergan Inc

11/09/17 / #20170320897

Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases

The present invention relates to a method for treating ocular inflammatory diseases in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2.. . ... Allergan Inc

10/26/17 / #20170304297

Immediate release abuse deterrent tablet

The invention relates to an abuse deterrent immediate release tablet.. . ... Allergan Inc

10/26/17 / #20170304268

Opioid receptor modulator dosage formulations

Abuse deterrent solid dosage formulations containing 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.. . ... Allergan Inc

10/12/17 / #20170290987

Aspiration and injection device

An aspiration and injection device is provided that can allow for ergonomic, safe, and precise aspiration of a target site and ejection of a medicament to the target site. The device can include a syringe barrel, a flange extender couplable to the barrel, and plunger that can be engaged by a hand and/or one or more finger of a user to perform aspiration and injection at a target site.. ... Allergan Inc

10/12/17 / #20170290652

Device and method for making a variable surface breast implant

Devices and methods are provided for making a variable textured breast implant when used in conjunction with a breast implant mandrel having a molding surface and a stem depending therefrom.. . ... Allergan Inc

10/05/17 / #20170283487

Immuno-based botulinum toxin serotype a activity assays

The present specification discloses snap-25 compositions, methods of making α-snap-25 antibodies that bind an epitope comprising a carboxyl-terminus at the p1 residue from the bont/a cleavage site scissile bond from a snap-25 cleavage product, α-snap-25 antibodies that bind an epitope comprising a carboxyl-terminus at the p1 residue from the bont/a cleavage site scissile bond from a snap-25 cleavage product, methods of detecting bont/a activity, and methods of detecting neutralizing α-bont/a antibodies.. . ... Allergan Inc

09/28/17 / #20170273886

Stable hydrogel compositions including additives

The present specification generally relates to an injectable dermal filler composition that includes crosslinked hyaluronic acid-based polymer and an antioxidant.. . ... Allergan Inc

09/21/17 / #20170266344

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.. ... Allergan Inc

09/21/17 / #20170266201

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

09/21/17 / #20170266138

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.. ... Allergan Inc

09/14/17 / #20170258878

Bladder injeciton paradigm for administration of botulinum toxins

Methods for treating a bladder dysfunction by injecting a clostridial derivative to a target site below the bladder midline are described.. . ... Allergan Inc

09/07/17 / #20170256010

Patent alert system

A computerized publication system comprising an automated alert generation platform for use in monitoring patents or other documents in the public domain, combined with a subscription management module.. . ... Allergan Inc

08/31/17 / #20170248602

Immuno-based retargeted endopeptidase activity assays

The present specification discloses a retargeted endopeptidase pharmaceutical wherein the activity has been determined by the methods disclosed.. . ... Allergan Inc

08/10/17 / #20170224873

Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation

. . Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.. ... Allergan Inc

08/10/17 / #20170224786

Botulinum toxin compositions

A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100.. . ... Allergan Inc

08/03/17 / #20170218334

Cells useful for immuno-based botulinum toxin serotype a activity assays

The present specification discloses clonal cell lines susceptible to bont/a intoxication, methods of producing such clonal cell lines, and methods of detecting botulinum toxin serotype a activity using such clonal cell lines.. . ... Allergan Inc

08/03/17 / #20170216488

Stable hydrogel compositions including additives

Dermal filler hydrogel compositions, methods of making them, and methods of using them to treat soft tissue conditions, such as wrinkles, are provided. The compositions contain a crosslinked hyaluronic acid-based polymer and one or more additional ingredients, and are stable to sterilization by heat and/or pressure treatment. ... Allergan Inc

08/03/17 / #20170216414

Dermal filler

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.. . ... Allergan Inc

08/03/17 / #20170216326

Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of formyl peptide receptor 2 (fpr2).. . ... Allergan Inc

08/03/17 / #20170216253

Ketorolac tromethamine compositions for treating or preventing ocular pain

Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.. ... Allergan Inc

07/27/17 / #20170209532

Two part formulation system for ophthalmic delivery

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. ... Allergan Inc

07/06/17 / #20170189412

Androgen composition for treating an opthalmic condition

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. ... Allergan Inc

06/29/17 / #20170183298

Carbamoyl hydrazine derivatives as formyl peptide modulators

The present invention relates to carbamoyl hydrazine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the fpr receptor.. . ... Allergan Inc

06/29/17 / #20170183293

Novel ep4 agonists as therapeutic compounds

Described herein are compounds that are ep4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of ep4 receptors.. . ... Allergan Inc

06/29/17 / #20170182064

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described; comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. . ... Allergan Inc

06/29/17 / #20170182062

4-pregenen-11beta-17-21-triol-3,20-dione derivatives

The present invention relates to novel 4-pregenen-11β-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.. ... Allergan Inc

06/29/17 / #20170182028

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

06/22/17 / #20170174858

Porogen compositions, methods of making and uses

Provided are porogen compositions and methods of using such porogen compositions in the manufacture of porous materials, for example, porous silicone elastomers. The porogens generally include comprising a core material and shell material different from the core material. ... Allergan Inc

06/22/17 / #20170174664

Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

06/22/17 / #20170173318

Multi-site injection system

A multi-site injection system includes a plurality of medicament delivering needles/microprotrusions, a needle/microprotrusion support, a supply of medicament, and a mechanism for providing the medicament to the plurality of needles/microprotrusions in order to effect delivery into a stratum corneum of a user.. . ... Allergan Inc

06/22/17 / #20170173123

Botulinum toxin treatments of neurological and neuropsychiatric disorders

Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.. ... Allergan Inc

06/22/17 / #20170172983

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

06/22/17 / #20170172982

Methods of treating alpha adrenergic mediated conditions

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.. ... Allergan Inc

06/22/17 / #20170172959

D-serine for the treatment of visual system disorders

The present invention relates to therapeutic methods using pharmaceutical compositions comprising one or a combination of co-agonists at the n-methyl-d-aspartate receptor for the treatment of visual system disorders.. . ... Allergan Inc

06/22/17 / #20170172957

D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders

The present invention relates to pharmaceutical compositions comprising d-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.. . ... Allergan Inc

06/08/17 / #20170157207

Method of treating conditions of the eye with an anti-vegf darpin

Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.. . ... Allergan Inc

06/08/17 / #20170157138

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

06/01/17 / #20170152224

Novel prostamides for the treatment of glaucoma and related diseases

Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.. ... Allergan Inc

06/01/17 / #20170151367

Dry dermal filler compositions and methods of reconstitution

Dermal fillers are provided, particularly hyaluronic acid-based dermal fillers containing additives, for example, unstable additives, the dermal fillers being provided in an anhydrous state for extended shelf life.. . ... Allergan Inc

06/01/17 / #20170151261

Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations

A combination of a prostaglandin ep4 agonist and an effective amount of: a prostaglandin ep2 agonist, a skin growth factor, a small peptide, a small inhibitory rna targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine a2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars.. . ... Allergan Inc

06/01/17 / #20170151217

Stabilized oxymetazoline formulations and their uses

The present invention provides stabilized cream formulations of oxymetazoline and uses thereof. The present invention also provides a method of treating facial erythema associated with rosacea in a patient in need of such treatment, comprising topically administering once or twice daily to the site of erythema on the face of the patient a pharmaceutical composition comprising 0.5%, 1.0% or 1.5% oxymetazoline or a pharmaceutically acceptable salt thereof as the sole active ingredient.. ... Allergan Inc

05/18/17 / #20170136145

Dermal filler compositions including antioxidants

. . Provided are injectable, hyaluronic acid-based hydrogel compositions including conjugated vitamins.. . ... Allergan Inc

05/18/17 / #20170136106

Botulinum toxin administration for treatment of neurogenic detrusor overactivity associated urinary incontinence

Methods for treating urinary incontinence associated with neurogenic detrusor overactivity (ndo) and for reducing need for or frequency of clean intermittent catherization (cic) by injecting a clostridial derivative to the bladder of a patient are disclosed.. . ... Allergan Inc

05/11/17 / #20170128552

Methods for treating headache

A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type a and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache.. ... Allergan Inc

05/04/17 / #20170119737

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. . ... Allergan Inc

05/04/17 / #20170119703

Methods of treatment of acne vulgaris using topical dapsone compositions

Dapsone compositions can be useful for treating acne. The methods and formulations disclosed herein show efficacy for treating acne vulgaris and/or post inflammatory hyperpigmentation.. ... Allergan Inc

04/27/17 / #20170112853

Hypotensive lipid and timolol compositions and methods of using same

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. ... Allergan Inc

04/20/17 / #20170107279

Heavy chain only antibodies to ang-2

Disclosed herein are monospecific hcab antibodies with antigen-binding specificity to ang-2 and bispecific antibodies with antigen-binding specificities to ang-2 and vegf or pdgf.. . ... Allergan Inc

04/20/17 / #20170107210

Pyridyl benzothiophenes as kinase inhibitors

This invention is directed to compounds, which are useful as protein kinase (pk) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.. . ... Allergan Inc

04/13/17 / #20170100334

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

04/06/17 / #20170096423

Antagonists acting at multiple prostaglandin receptors for the treatment of inflammation

. . Compounds, processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the fp, dp, ep1, ep4, ip, dp1, fp and tp prostaglandin (pg) receptors thereby providing a general anti-inflammatory response.. . ... Allergan Inc

04/06/17 / #20170096401

Imidazole derivatives as formyl peptide receptor modulators

The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor.. . ... Allergan Inc

04/06/17 / #20170095466

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

04/06/17 / #20170095438

Compositions and methods for transdermal oxybutynin therapy

The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as n-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. ... Allergan Inc

03/30/17 / #20170087273

Bioerodible matrix for tissue involvement

Disclosed herein are polyurethane polymer matrices with a porosity of from about 20 microns to about 90 microns that are useful in promoting closure and protection of incision sites; supporting the lower pole position of breast implants; and providing a partial or complete covering of breast implants to provide a beneficial interface with host tissue and to reduce the potential for malpositioning or capsular contracture. The disclosed matrices can be seeded with mammalian cells.. ... Allergan Inc

03/30/17 / #20170087163

Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. ... Allergan Inc

03/30/17 / #20170087102

Topical dapsone and dapsone/adapalene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

03/23/17 / #20170081304

Quaternary ammonium alkyl esters as stable prodrugs

Disclosed herein are compounds according to formulas 1-12, compositions comprising these compounds, and methods of lowering intraocular pressure (iop) or causing hair growth, and methods of using the same.. . ... Allergan Inc

03/23/17 / #20170080154

Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form

Described herein are injection devices capable of automatically injecting substances into the soft tissue of a patient. The devices can inject low to high viscosity materials at predetermined, user selected injection rates, allowing the operator more control than a traditional syringe. ... Allergan Inc

03/23/17 / #20170079956

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory t cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.. . ... Allergan Inc

03/16/17 / #20170071953

Microsphere drug delivery system for sustained intraocular release

Disclosed are biodegradable microspheres between 40 μm and 200 μm in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. ... Allergan Inc

03/16/17 / #20170071882

Dapsone to treat rosacea

The methods described herein provide treatment of rosacea using topical formulations of dapsone. The methods also provide treatment of rosacea with topical dapsone in combination with other active agents, including metronidazole. ... Allergan Inc

03/16/17 / #20170071853

Intracameral sustained release therapeutic agent implants

Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. ... Allergan Inc

03/16/17 / #20170071726

Reinforced prosthetic implant with flexible shell

A fluid-filled soft prosthetic implant having a shell with a reinforced shell wall. The soft prosthetic implant may be for breast reconstruction or augmentation, or to restore the normal appearance of soft tissue in the buttocks, chin, calf, etc. ... Allergan Inc

03/09/17 / #20170066738

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.. ... Allergan Inc

03/09/17 / #20170065612

Hypotensive lipid-containing biodegradable intraocular implants and related implants

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

03/09/17 / #20170065610

Compositions & methods for lowering intraocular pressure

Disclosed herein are compositions for lowering intraocular pressure (iop) of an eye comprising a combination iop-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing iop in the eye of a subject.. ... Allergan Inc

03/02/17 / #20170056412

Prostamide-containing intraocular implants and methods of use thereof

. . Prostamide-containing intraocular implants that biodegrade in the eye and that are effective for reducing intraocular pressure in an eye for a sustained period. The implants generally contain a prostamide, such as bimatoprost, and at least three distinct biodegradable polymers selected from polylactide and poly(lactide-co-glycolide) polymers and are optimized for placement in and compatibility with the anterior chamber of the eye, particularly the anterior chamber angle. ... Allergan Inc

03/02/17 / #20170056399

Sustained drug delivery implant

Biocompatible intraocular implants may include a brimonidine free base and a biodegradable polymer associated with the brimonidine free base to facilitate the release of the brimonidine free base into an eye with the polymer matrix lasts a period of time of not more than twice the drug release duration, but more than the drug release duration.. . ... Allergan Inc

03/02/17 / #20170055561

Conditioned cell culture medium compositions and methods of use

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. ... Allergan Inc

02/23/17 / #20170049559

Lighter weight implant

A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.. ... Allergan Inc

02/16/17 / #20170044247

Heavy chain only antibodies to pdgf

Disclosed herein are monospecific hcab antibodies with antigen-binding specificity to pdgf and bispecific antibodies with antigen-binding specificities to pdgf-2 and vegf or to pdgf and ang-2.. . ... Allergan Inc

02/16/17 / #20170042984

Methods for treatment of incontinence associated with sexual activity

The invention provides compositions and methods for treating incontinence associated with sexual activity.. . ... Allergan Inc

02/02/17 / #20170029469

Cyclosporin analogs

Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.. . ... Allergan Inc

02/02/17 / #20170028102

Silk medical devices

Laminate medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble silk film.. ... Allergan Inc

02/02/17 / #20170027679

Medical device with anti adhesive property

Laminate or knitted medical devices and methods using such devices to support soft tissues and/or to reduce formation of post-operative adhesions. The medical devices can comprise a layer of a knitted silk mesh to which has been fused a water soluble or insoluble silk film or silk sponge, and/or a layer of a knitted silk mesh which was co-knitted with one, two or three layers of silk or non-silk fabric.. ... Allergan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Allergan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###